Page 338 of 1,034: studies 3,371 to 3,380 of 10,336, newest first. Back to the depression overview
Proceedings of the National Academy of Sciences May 5, 2026 Roberto Malinow
Ketamine has been shown to reduce depression and suicidality in individuals resistant to treatment by other drugs. Exactly how ketamine works is not known. Here, I propose a new hypothesis that involves synaptic and circuit plasticity and may lead to enhanced efficacy in treating depression as well as other conditions.
Acta Psychologica May 1, 2026 Cristina Martinez Montes, Birgit Penzenstadler
Knowledge workers often face high stress due to deadlines and overcommitment, which negatively impacts their well-being. They have specific characteristics and challenges, such as a tendency to work in isolation or in intense team environments, sleep deprivation, and making decisions under pressure. To support preventive measures, this study provides a comprehensive, systematic understanding of...
Biological Psychiatry Global Open Science May 1, 2026 Mario Bogdanov, Jason N Scott, Shiba M Esfand et al. 1 citation
Ketamine is increasingly used as a therapeutic option for treatment-resistant depression (TRD) due to its rapid antidepressant properties; however, the mechanisms underlying these effects remain elusive. Preclinical evidence suggests ketamine acts on neural pathways implicated in reward processing, but translational efforts have proven challenging due to a lack of paradigms allowing for...
Medicine May 1, 2026 Hai-Lin Hu, Qi-Zhou Huang, Ping-Xia Xie
Esketamine, the S-enantiomer of ketamine, has emerged as a rapid-acting antidepressant with unique mechanisms. This narrative review synthesizes current evidence on its clinical applications, safety, and regulatory status based on peer-reviewed literature published between January 2000 and March 2024, searched in PubMed, Web of Science, and the Cochrane Library. Esketamine exerts its effects...
Cureus May 1, 2026 Amalesh S Honnekeri
Treatment-resistant depression (TRD) remains a significant clinical concern, particularly in patients who do not achieve adequate response with conventional antidepressant therapies. Ketamine and esketamine, which act on glutamatergic pathways, have been introduced into clinical practice as alternative therapeutic approaches within interventional psychiatry. This narrative review outlines key...
Journal of Psychopharmacology May 1, 2026 Grace Viljoen, Henrik Walter, Antonia Bendau et al. 3 citations
Psychedelic-assisted therapy (PAT) has demonstrated substantial efficacy across a range of mental disorders. However, heterogeneity between patients confers differential responsiveness. This systematic review aims to explore factors which may predict therapeutic responses to PAT. A systematic search was performed from inception through to March 2024 and studies that assessed predictors of...
Translational Psychiatry April 24, 2026 Matt Butler, Ellen Moore, James Rucker et al. 1 citation
Hallucinogen persisting perception disorder (HPPD) is characterised by episodes of altered perception linked to past psychoactive drug use, accompanied by distress and functional impairment. To date, clinical characterisation has been limited in scale. Using TriNetX, a global federated health research network of electronic health records, we conducted a retrospective cohort study comparing...
bioRxiv : the preprint server for biology April 17, 2026 Pasha A. Davoudian, Quan Jiang, Cory A. Knox et al. preprint
Psychedelics show therapeutic potential for treating psychiatric disorders. While studies have emphasized the roles of cortical pyramidal cells, GABAergic neurons also express serotonin receptors and are therefore likely targets of psychedelics. In this study, we determine the effect of psilocybin on the activity dynamics of major GABAergic cell types in the mouse medial frontal cortex....
Journal of Psychopharmacology April 16, 2026 Minna Chang, Allan H. Young, Mario F Juruena
Previous systematic reviews and meta-analyses have reported impressive antidepressant effects of ketamine in treatment-resistant depression (TRD). While ketamine has been compared with electroconvulsive therapy (ECT), the gold standard treatment, the extent and durability of its antidepressant effects over longer periods remain unclear. To our knowledge, this is the first systematic review...
Journal of Intensive Care Medicine April 16, 2026 Vrutti Patel, Saurabh Sujanyal, Lekhya Raavi et al.
BackgroundKetamine has demonstrated efficacy in treatment-resistant depression, primarily in psychiatric or outpatient populations. Its use in ICU patients remains underexplored, with limited data beyond case reports and small series. This study evaluated the association between subanesthetic ketamine infusions and improvement in depressive symptoms and hemodynamic changes in ICU...